Galectin Book Value Per Share from 2010 to 2024

GALT Stock

USD 2.78 0.06 2.21%

Galectin Therapeutics Book Value Per Share yearly trend continues to be comparatively stable with very little volatility. Book Value Per Share is likely to outpace its year average in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Galectin Therapeutics according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

(1.00)

Current Value

(0.95)

Quarterly Volatility

0.63199702

Credit Downgrade

Yuan Drop

Covid

Check Galectin Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galectin Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 40 M, Interest Expense of 2.7 M or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0016 or Days Sales Outstanding of 0.0. Galectin financial statements analysis is a perfect complement when working with Galectin Therapeutics Valuation or Volatility modules.

Check out the analysis of Galectin Therapeutics Correlation against competitors.

For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

Latest Galectin Therapeutics' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Galectin Therapeutics over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Galectin Therapeutics' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galectin Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (1.01) X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Galectin Book Value Per Share Regression Statistics

	Arithmetic Mean	0.15
	Geometric Mean	0.29
	Coefficient Of Variation	416.51
	Mean Deviation	0.49
	Median	0.18
	Standard Deviation	0.63
	Sample Variance	0.40
	Range	2.0398
	R-Value	(0.54)
	Mean Square Error	0.31
	R-Squared	0.29
	Significance	0.04
	Slope	(0.08)
	Total Sum of Squares	5.59

Galectin Book Value Per Share History

	2024	-0.95
	2023	-1.0
	2022	-0.57
	2021	0.0153
	2020	0.42
	2019	0.87
	2018	0.18

Other Fundumenentals of Galectin Therapeutics

Tangible Book Value Per Share

Galectin Therapeutics Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.25	-0.32	-0.5	0.25	0.2	1.0	-0.51	0.68	-0.03	-0.46	0.01	0.33	0.69	0.79	0.78	-0.67
Total Stockholder Equity	0.25		-0.99	0.55	-0.83	-0.89	0.26	-0.11	-0.22	0.31	0.03	0.75	0.94	-0.27	0.06	0.12	0.35
Net Debt	-0.32	-0.99		-0.52	0.8	0.86	-0.33	0.18	0.18	-0.26	-0.03	-0.77	-0.94	0.23	-0.09	-0.15	-0.32
Retained Earnings	-0.5	0.55	-0.52		-0.83	-0.8	-0.49	0.39	-0.89	0.24	0.6	0.58	0.56	-0.89	-0.6	-0.54	0.83
Accounts Payable	0.25	-0.83	0.8	-0.83		0.97	0.24	-0.04	0.56	-0.26	-0.34	-0.86	-0.7	0.61	0.39	0.33	-0.71
Total Liab	0.2	-0.89	0.86	-0.8	0.97		0.19	-0.11	0.52	-0.31	-0.25	-0.83	-0.78	0.57	0.33	0.27	-0.68
Total Current Assets	1.0	0.26	-0.33	-0.49	0.24	0.19		-0.51	0.67	-0.03	-0.45	0.02	0.34	0.68	0.79	0.78	-0.66
Short Term Debt	-0.51	-0.11	0.18	0.39	-0.04	-0.11	-0.51		-0.42	0.55	0.47	-0.1	-0.02	-0.33	-0.34	-0.35	0.25
Common Stock	0.68	-0.22	0.18	-0.89	0.56	0.52	0.67	-0.42		0.01	-0.56	-0.21	-0.28	0.99	0.76	0.71	-0.86
Property Plant Equipment	-0.03	0.31	-0.26	0.24	-0.26	-0.31	-0.03	0.55	0.01		0.32	0.19	0.33	0.04	0.27	0.3	-0.04
Current Deferred Revenue	-0.46	0.03	-0.03	0.6	-0.34	-0.25	-0.45	0.47	-0.56	0.32		0.2	0.11	-0.5	-0.3	-0.28	0.34
Net Receivables	0.01	0.75	-0.77	0.58	-0.86	-0.83	0.02	-0.1	-0.21	0.19	0.2		0.57	-0.26	-0.22	-0.2	0.43
Net Tangible Assets	0.33	0.94	-0.94	0.56	-0.7	-0.78	0.34	-0.02	-0.28	0.33	0.11	0.57		-0.28	0.13	0.2	0.3
Capital Surpluse	0.69	-0.27	0.23	-0.89	0.61	0.57	0.68	-0.33	0.99	0.04	-0.5	-0.26	-0.28		0.76	0.7	-0.88
Net Invested Capital	0.79	0.06	-0.09	-0.6	0.39	0.33	0.79	-0.34	0.76	0.27	-0.3	-0.22	0.13	0.76		0.99	-0.86
Net Working Capital	0.78	0.12	-0.15	-0.54	0.33	0.27	0.78	-0.35	0.71	0.3	-0.28	-0.2	0.2	0.7	0.99		-0.8
Capital Stock	-0.67	0.35	-0.32	0.83	-0.71	-0.68	-0.66	0.25	-0.86	-0.04	0.34	0.43	0.3	-0.88	-0.86	-0.8

Click cells to compare fundamentals

About Galectin Therapeutics Financial Statements

Galectin Therapeutics shareholders use historical fundamental indicators, such as Book Value Per Share, to determine how well the company is positioned to perform in the future. Although Galectin Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Galectin Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Galectin Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Book Value Per Share	(1.00)	(0.95)
Tangible Book Value Per Share	(1.00)	(0.95)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC